Circulating microRNA expression potentially identifies new TED biomarkers

Article

New research identifies potential new TED biomarkers based on the disease activity or inactivity.

Korean researchers identified circulating microRNA (miRNA) expressions in patients with thyroid eye disease (TED) based on the disease activity or inactivity, thus providing new insight into the biological mechanisms driving the disease.1

The perceived importance of miRNAs has been increasing in recent decades. Specifically, the researchers explained, miRNAs are a class of noncoding RNAs that post-transcriptionally regulate gene expression and are involved in a wide range of physiological and pathological processes.2

“In the past few decades, miRNAs have received increasing attention due to their roles in regulating gene expression. Deregulation of miRNAs results in mRNA dysfunction, leading to the development of pathologic conditions.”

Namju Kim, MD, lead author from the Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Korea, and colleagues described a study with the goal of characterizing the miRNA expression signatures in patients with TED and identify miRNA biomarkers of disease activity.

Kim stated, “Although enormous progress has been made in elucidating the pathogenesis of TED, the exact mechanism of TED remains elusive, and therapeutic challenges and dilemmas remain."

The team first isolated the total RNA from the sera of 10 patients with TEDand 5 healthy controls using an assay to comprehensively analyze 798 miRNA expression profiles. Analysis of specific miRNA signatures, mRNA target pathway analysis, and network analysis were performed, they explained.

The patients with TED were divided into two groups based on the activity or inactivity of the disease. Upon analysis of the miRNAs, the investigators found that 173 differentially down-regulated miRNAs were identified in the patients with TED compared with the healthy controls.

“Ten circulating miRNAs were differentially expressed between the active and inactive TED groups and regarded as candidate biomarkers for TED activity: 1 up-regulated miRNA, miR-29c-3p; and nine down-regulated miRNAs, miR-4286, miR-941, miR-571, miR-129-2-3p, miR-484, miR-192-5p, miR-502-3p, miR-597-5p, and miR-296-3p, the authors reported.

In a validation cohort, the expression levels of 2 of the down-regulated miRNAs, miR-484 and miR-192-5p, were significantly lower in the patients withactive TED compared with the patients with inactive TED.

The authors concluded that becausethe expression levels of miR-484 and miR-192-5p differed significantly between the active and inactive TED groups, these miRNAs have the potential to serve as circulating serum biomarkers of disease activity. However, they advised that larger futurestudies should validate the current findings of these miRNAs.

References
1. Kim N, Choung H, Kim YJ, et al.Serum microRNA as a potential biomarker for the activity of thyroid eye disease. Sci Rep. 2023;13:234; https://doi.org/10.1038/s41598-023-27483-w.
2. Xiao C, Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell. 2009;136:26–36.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
© 2025 MJH Life Sciences

All rights reserved.